Cytokinetics EVP Sells $293K in Stock

Fady Ibraham Malik offloads 4,500 shares of the biotech company's stock.

Apr. 9, 2026 at 11:54am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up of heavy, tangible banking mechanics and objects, representing the secure infrastructure underlying financial markets.An extreme close-up of the complex inner workings of the financial industry, conveying a sense of institutional strength and stability.South San Francisco Today

Cytokinetics, Incorporated (NASDAQ:CYTK) Executive Vice President Fady Ibraham Malik sold 4,500 shares of the company's stock on Tuesday, April 7th. The shares were sold at an average price of $65.11, resulting in a total transaction of $292,995.

Why it matters

Insider stock sales can provide insight into a company's performance and the confidence of its leadership. Malik's sale represents a 2.84% decrease in his position, potentially signaling a shift in his outlook on Cytokinetics' prospects.

The details

Following the transaction, Malik still owns 153,902 shares in the company, valued at $10,020,559.22. The sale was executed under a pre-arranged Rule 10b5-1 trading plan.

  • The shares were sold on Tuesday, April 7th, 2026.
  • Malik's previous trades were not specified in the source article.

The players

Fady Ibraham Malik

The Executive Vice President of Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

Insider stock sales can provide insight into a company's performance and the confidence of its leadership. While Malik's sale represents a modest decrease in his position, it does not necessarily indicate any broader concerns about Cytokinetics' outlook.